Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2006.10.2509 on May 7 2007

Journal of Clinical Oncology, Vol 25, No 17 (June 10), 2007: pp. 2434-2441
© 2007 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cavo, M.
Right arrow Articles by Baccarani, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cavo, M.
Right arrow Articles by Baccarani, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study

Michele Cavo, Patrizia Tosi, Elena Zamagni, Claudia Cellini, Paola Tacchetti, Francesca Patriarca, Francesco Di Raimondo, Ettore Volpe, Sonia Ronconi, Delia Cangini, Franco Narni, Affra Carubelli, Luciano Masini, Lucio Catalano, Mauro Fiacchini, Antonio de Vivo, Alessandro Gozzetti, Antonio Lazzaro, Sante Tura, Michele Baccarani

From the Istituto di Ematologia ed Oncologia Medica [Seràgnoli], Università di Bologna, Bologna; Clinica Ematologia, Università di Udine, Udine; Cattedra di Ematologia, Università di Catania, Catania; Servizio di Ematologia, Avellino; Sezione di Ematologia, Università di Modena, Modena; Unità Operativa di Ematologia, Cagliari; Servizio di Ematologia, Reggio Emilia; Divisione di Ematologia, Università Federico II, Napoli; Divisione di Ematologia e Trapianti, Università di Siena, Siena; and Oncologia Medica ed Ematologia, Piacenza

Address reprint requests to Michele Cavo, MD, [Seràgnoli] Institute of Hematology and Medical Oncology, via Massarenti 9, 40138, Bologna, Italy; e-mail: mcavo{at}med.unibo.it

Purpose We performed a prospective, randomized study of single (arm A) versus double (arm B) autologous stem-cell transplantation (ASCT) for younger patients with newly diagnosed multiple myeloma (MM).

Patients and Methods A total of 321 patients were enrolled onto the study and were randomly assigned to receive either a single course of high-dose melphalan at 200 mg/m2 (arm A) or melphalan at 200 mg/m2 followed, after 3 to 6 months, by melphalan at 120 mg/m2 and busulfan at 12 mg/kilogram (arm B).

Results As compared with assignment to the single-transplantation group (n = 163 patients), random assignment to receive double ASCT (n = 158 patients) significantly increased the probability to attain at least a near complete response (nCR; 33% v 47%, respectively; P = .008), prolonged relapse-free survival (RFS) duration of 18 months (median, 24 v 42 months, respectively; P < .001), and significantly extended event-free survival (EFS; median, 23 v 35 months, respectively; P = .001). Administration of a second transplantation and of novel agents for treating sequential relapses in up to 50% of patients randomly assigned to receive a single ASCT likely contributed to prolong the survival duration of the whole group, whose 7-year rate (46%) was similar to that of the double-transplantation group (43%; P = .90). Transplantation-related mortality was 3% in arm A and 4% in arm B (P = .70).

Conclusion In comparison with a single ASCT as up-front therapy for newly diagnosed MM, double ASCT effected superior CR or nCR rate, RFS, and EFS, but failed to significantly prolong overall survival. Benefits offered by double ASCT were particularly evident among patients who failed at least nCR after one autotransplantation.

published online ahead of print at www.jco.org on May 7, 2007.

Supported by Università di Bologna, Progetti di Ricerca Fondamentale Orientata (M.C.); Ministero dell'Università e Ricerca Scientifica, progetto FIRB, RBAU012E9A_001 (M.C.); and Fondazione Carisbo.

Presented in part at the 46th Annual Meeting of the American Society of Hematology, December 6-9, 2004, San Diego, CA.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
JNCI J Natl Cancer InstHome page
J. Mehta
Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
J Natl Cancer Inst, October 21, 2009; 101(20): 1430 - 1431.
[Full Text] [PDF]


Home page
JCOHome page
M. Cavo, F. Di Raimondo, E. Zamagni, F. Patriarca, P. Tacchetti, A. F. Casulli, S. Volpe, G. Perrone, A. Ledda, M. Ceccolini, et al.
Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma
J. Clin. Oncol., October 20, 2009; 27(30): 5001 - 5007.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J.-L. Harousseau, M. Attal, and H. Avet-Loiseau
The role of complete response in multiple myeloma
Blood, October 8, 2009; 114(15): 3139 - 3146.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. M. Giarin, L. Giaccone, R. Sorasio, C. Sfiligoi, B. Amoroso, F. Cavallo, A. Cipriani, A. Palumbo, and M. Boccadoro
Serum Free Light Chain Ratio, Total {kappa}/{lambda} Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Clin. Chem., August 1, 2009; 55(8): 1510 - 1516.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. Kumar and B. Djulbegovic
Response: Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
J Natl Cancer Inst, July 1, 2009; 101(13): 966 - 967.
[Full Text] [PDF]


Home page
NEJMHome page
J.-L. Harousseau and P. Moreau
Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
N. Engl. J. Med., June 18, 2009; 360(25): 2645 - 2654.
[Full Text] [PDF]


Home page
BloodHome page
M. Rotta, B. E. Storer, F. Sahebi, J. A. Shizuru, B. Bruno, T. Lange, E. D. Agura, P. A. McSweeney, M. A. Pulsipher, P. Hari, et al.
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
Blood, April 2, 2009; 113(14): 3383 - 3391.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. Kumar, M. A. Kharfan-Dabaja, A. Glasmacher, and B. Djulbegovic
Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
J Natl Cancer Inst, January 21, 2009; 101(2): 100 - 106.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Moreau, F. Garban, M. Attal, M. Michallet, G. Marit, C. Hulin, L. Benboubker, C. Doyen, M. Mohty, I. Yakoub-Agha, et al.
Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma
Blood, November 1, 2008; 112(9): 3914 - 3915.
[Full Text] [PDF]


Home page
BloodHome page
L. Rosinol, J. A. Perez-Simon, A. Sureda, J. de la Rubia, F. de Arriba, J. J. Lahuerta, J. D. Gonzalez, J. Diaz-Mediavilla, B. Hernandez, J. Garcia-Frade, et al.
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
Blood, November 1, 2008; 112(9): 3591 - 3593.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
S. V. Rajkumar
Treatment of Myeloma: Cure vs Control
Mayo Clin. Proc., October 1, 2008; 83(10): 1142 - 1145.
[Full Text] [PDF]


Home page
JCOHome page
J. San-Miguel, J.-L. Harousseau, D. Joshua, and K. C. Anderson
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
J. Clin. Oncol., June 1, 2008; 26(16): 2761 - 2766.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H. M. Lazarus, G. L. Phillips, R. H. Herzig, D. D. Hurd, S. N. Wolff, and G. P. Herzig
High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later
J. Clin. Oncol., May 10, 2008; 26(14): 2240 - 2243.
[Full Text] [PDF]


Home page
BloodHome page
J. Mehta
One or two autografts for myeloma?
Blood, April 1, 2008; 111(7): 3899 - 3900.
[Full Text] [PDF]


Home page
BloodHome page
R. A. Kyle and S. V. Rajkumar
Multiple myeloma
Blood, March 15, 2008; 111(6): 2962 - 2972.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Jagannath
Is tandem autotransplantation necessary in myeloma?
Blood, February 15, 2008; 111(4): 1751 - 1752.
[Full Text] [PDF]


Home page
BloodHome page
A. Abdelkefi, S. Ladeb, L. Torjman, T. B. Othman, A. Lakhal, N. B. Romdhane, H. E. Omri, M. Elloumi, H. Belaaj, R. Jeddi, et al.
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial
Blood, February 15, 2008; 111(4): 1805 - 1810.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W. Bensinger
Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
J. Clin. Oncol., January 20, 2008; 26(3): 480 - 492.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
J.-L. Harousseau
Induction Therapy in Multiple Myeloma
Hematology, January 1, 2008; 2008(1): 306 - 312.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
S. V. Rajkumar and S. R. Hayman
Controversies Surrounding the Initial Treatment of Multiple Myeloma
ASCO Educational Book, January 1, 2008; 2008(1): 369 - 374.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Dingli, J. M. Pacheco, G. S. Nowakowski, S. K. Kumar, A. Dispenzieri, S. R. Hayman, M. Q. Lacy, D. A. Gastineau, and M. A. Gertz
Relationship Between Depth of Response and Outcome in Multiple Myeloma
J. Clin. Oncol., November 1, 2007; 25(31): 4933 - 4937.
[Abstract] [Full Text] [PDF]


Home page
CA Cancer J ClinHome page
J. A. Katzel, P. Hari, and D. H. Vesole
Multiple Myeloma: Charging Toward a Bright Future
CA Cancer J Clin, September 1, 2007; 57(5): 301 - 318.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
M. Attal, P. Moreau, H. Avet-Loiseau, and J.-L. Harousseau
Stem Cell Transplantation in Multiple Myeloma
Hematology, January 1, 2007; 2007(1): 311 - 316.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online